Atara Biotherapeutics Inc (NASDAQ:ATRA)
| 2.92 BATS BZX Real-Time Price As of 1:56pm ET |  -0.06 / -2.02%Today’s Change | 2.66 Today|||52-Week Range 10.01 | -11.13% Year-to-Date |
Latest ATRA News | Press Releases
| Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Mar 24 / Zacks.com - Paid Partner Content | Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study Mar 21 / Zacks.com - Paid Partner Content |
| 89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study Mar 23 / Zacks.com - Paid Partner Content | Esperion (ESPR) Plummets 54% Over Milestone Payment Row Mar 17 / Zacks.com - Paid Partner Content |
| Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study Mar 23 / Zacks.com - Paid Partner Content | Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study Mar 17 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.98 |
| Today’s open | 2.96 |
| Day’s range | 2.92 - 2.99 |
| Volume | 11,723 |
| Average volume (3 months) | 1,313,824 |
| Market cap | $275.3M |
Data as of 1:56pm ET, 03/28/2023
Growth & Valuation
| Earnings growth (last year) | +38.36% |
| Earnings growth (this year) | +8.94% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +212.55% |
| P/E ratio | NM |
| Price/Sales | 5.26 |
| Price/Book | 2.16 |
Competitors
Data as of 1:57pm ET, 03/28/2023
Financials
| Next reporting date | May 10, 2023 |
| EPS forecast (this quarter) | -$0.37 |
| Annual revenue (last year) | $63.6M |
| Annual profit (last year) | -$228.3M |
| Net profit margin | -359.12% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Thousand Oaks, California |
Forecasts
